Total Funding
52
Total FundingSeries B raised
Growth Score
pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
170157
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Acquired by 
Tectonic Therapeutic
Jeffrey Medin: Scientific FounderPast Role: University of Toronto, Professor
Christopher Paige: Scientific FounderPast Role: Arthritis and Autoimmunity Research Centre, Founding Director
About the Company
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious
debilitating disease.
Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.
